MILAN, Italy, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Olon Group announces the construction of a cutting-edge High Potency API suite.

A GMP High Potency Active Pharmaceutical Ingredient (HPAPI) suite, currently under construction at the Olon USA site in Concord, Ohio, is the center of excellence for early development of APIs within the Olon Group. This adds to the significant commercial scale expertise and capabilities of the Segrate and Rodano sites near Milan, Italy, and it is part of an important growth of capabilities for handling HPAPI in the group where the company has invested overall around 40 million Euro in the last few years.

“Our High Potency API suite is not just a facility; it's a gateway to new possibilities. Engineered to meet the most stringent safety standards for R&D and GMP processes, this suite will operate for materials with an Occupational Exposure Limit (OEL) of <1 µg/m3 (OEB5, SafeBridge 3). This level of containment is essential for working with materials classified as highly potent, especially in the realm of anti-cancer drugs, where safety is paramount. This is highly integrated with the already existing capability in our Italian sites such as Rodano, to produce highly potent APIs in large-scale product batches ranging from 30 to 150 kg. Today we are one of the few API suppliers to offer the range of specific integrated capabilities necessary to support the customer from the first clinical phase up to industrialization, regardless of the quantity of product needed and batch size required and regardless of the ongoing molecule development phase,” stated Giorgio Bertolini, Senior VP R&D Olon Group.

The High Potency API suite will provide a secure and self-contained environment for working with these materials, ensuring the safety of our operators and staff as they develop the synthetic process or manufacture your clinical grade materials. As additional safety data becomes available, the site can adapt protocols accordingly, allowing scale up for 1-10 µg/m³ OEL (OEB4, SafeBridge 3A) or lower bands into the pilot plant using continuous liner and the portable filter dryer which is rated to OEB5.

www.olonspa.com

Media contact
Sabrina Spina
sspina@olonspa.it – mobile 338.6674289

This item of content is a press release from a third party provider who make no warranties or representations in connection with this content and therefore PA can make no warranties in respect of its use.

Tags

More Like This

Olon is ready to host productions in the new facility dedicated to ultra-potent compounds

Olon Continues its Growth Path and Announces a New Acquisition

Olon, International API Supplier, Releases Its Annual Sustainability Report

Antheia and Olon Continue Partnership for Biomanufacturing Antheia’s Pipeline of KSMs and APIs for Essential Medicines

Olon Group Announces the Acquisition of GTP Bioways Group

Cambrex Completes $38 Million Capacity Expansion in High Point, North Carolina

ST Pharm breaks ground on 2nd State-of-the-Art Oligonucleotide Facility

Lubrizol’s Apisolex™ Polymer Wins Finished Formulation Award at CPhI Barcelona